Don't Just Read the News, Understand It.
Published loading...Updated

Ozempic and Wegovy May Have Landed 25,000 People in the ER—Here's the Scary Reason Why

  • A new study published in Annals of Internal Medicine found that semaglutide-based weight-loss drugs caused about 25,000 emergency room visits in the US from 2022 to 2023 due to adverse effects.
  • Researchers analyzed data from 82 hospitals collected between January 1, 2022, and December 31, 2023, focusing on gastrointestinal complications linked to semaglutide use.
  • Nearly 70 percent of the ER visits involved gastrointestinal issues like gastroparesis, with 15 percent of those visits resulting in hospitalization, while 15.6 percent were due to hypoglycemia.
  • Pieter Cohen, MD, study author, noted semaglutide rarely causes severe hospitalizing events but recommended clinicians counsel patients about GI risks and adjust antidiabetic drugs to reduce hypoglycemia.
  • These findings have prompted calls for stricter regulations enforcing medical oversight and mandatory monitoring before and during weight-loss injection therapy to improve patient safety.
Insights by Ground AI
Does this summary seem wrong?

19 Articles

All
Left
1
Center
3
Right
6
Lean Right

The shortage of obesity drugs may be over in Sweden. Therefore, the call for doctors to only prescribe the drugs to people with diabetes should be dropped, experts believe. But the Swedish Medical Products Agency is not changing its position.

·Stockholm, Sweden
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 60% of the sources lean Right
60% Right
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Independent Español broke the news in on Friday, May 2, 2025.
Sources are mostly out of (0)

You have read 1 out of your 5 free daily articles.

Join millions of well-informed readers who use Ground to compare coverage, check their news blindspots, and challenge their worldview.